Beigelman Leonid 13D and 13G filings for Aligos Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2022-02-10 4:19 pm Purchase | 2021-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | Beigelman Leonid | 74,894 4.700% | 3,000 (+4.17%) | Filing |
| 2021-02-11 4:16 pm Purchase | 2020-12-31 | 13G | Aligos Therapeutics, Inc. ALGS | Beigelman Leonid | 71,894 5.100% | 71,894 (New Position) | Filing |